JPMorgan Chase & Co. Reaffirms Underweight Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Key Points

• JPMorgan Chase & Co. has reaffirmed an "underweight" rating for Sarepta Therapeutics, reflecting a cautious stance among analysts following recent stock performance.
• Sarepta Therapeutics has received a mix of ratings, with four analysts rating it as a sell, eighteen as a hold, and seven as a buy, indicating varied investor sentiment.
• The company's stock recently opened at $12.89, down from a 52-week high of $150.48, highlighting significant volatility and concerns among investors.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "underweight" rating restated by analysts at JPMorgan Chase & Co. in a report issued on Friday,Benzinga reports.

Several other equities analysts also recently weighed in on SRPT. UBS Group reiterated a "neutral" rating on shares of Sarepta Therapeutics in a report on Monday. Barclays set a $18.00 target price on Sarepta Therapeutics and gave the company an "equal weight" rating in a research report on Tuesday. HC Wainwright restated a "sell" rating on shares of Sarepta Therapeutics in a research report on Tuesday. Citigroup began coverage on Sarepta Therapeutics in a research note on Tuesday. They set a "sell" rating for the company. Finally, Leerink Partnrs downgraded shares of Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Four investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $51.42.

Sarepta Therapeutics Stock Down 3.2%

Shares of NASDAQ SRPT opened at $12.89 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The company has a 50-day moving average price of $26.61 and a 200-day moving average price of $65.26. Sarepta Therapeutics has a 1 year low of $10.41 and a 1 year high of $150.48. The stock has a market capitalization of $1.27 billion, a P/E ratio of -4.79 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. During the same period last year, the company posted $0.73 EPS. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. On average, equities research analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. New York State Teachers Retirement System raised its stake in shares of Sarepta Therapeutics by 3.3% during the first quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock valued at $5,065,000 after acquiring an additional 2,512 shares in the last quarter. Exchange Traded Concepts LLC purchased a new stake in Sarepta Therapeutics in the first quarter valued at $479,000. GAMMA Investing LLC boosted its holdings in Sarepta Therapeutics by 4,682.8% in the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock valued at $2,607,000 after purchasing an additional 39,991 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Sarepta Therapeutics in the first quarter valued at $821,000. Finally, Cetera Investment Advisers raised its position in shares of Sarepta Therapeutics by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 11,174 shares of the biotechnology company's stock worth $1,359,000 after acquiring an additional 463 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.